公开(公告)号：US20210015950A1

公开(公告)日：2021-01-21

申请号：US17042772

申请日：2019-04-11

Applicant: Clarity Pharmaceuticals Limited

Inventor： Matthew John HARRIS ,  Sean LUMB

IPC: A61K51/04 ,  A61K49/10 ,  A61K9/08

Abstract: Aqueous formulations and kits of radiopharmaceutical compounds of general Formula (II) protected from radiolysis with stabilisers, such as L-methionine and gentisic acid, are disclosed, wherein the compounds are based on sarcophagine ligands coordinated to a radioisotope, such as 64-copper, and linked to a tetrazine group for reaction with tumour targeting antibodies having functional reactive groups such as trans-cyclooctene, processes of preparing said radioligand formulations, and uses thereof for radioimaging, diagnosing and treating cancer.

公开(公告)号：US20230330276A1

公开(公告)日：2023-10-19

申请号：US18339124

申请日：2023-06-21

Applicant: Clarity Pharmaceuticals Limited

Inventor： Matthew John HARRIS ,  Sean LUMB

IPC: A61K51/04 ,  A61K9/08 ,  A61K49/10

CPC classification number: A61K51/0482 ,  A61K9/08 ,  A61K49/106 ,  A61K51/0497 ,  A61P35/00

Abstract: Aqueous formulations and kits of radiopharmaceutical compounds of general Formula (II) protected from radiolysis with stabilisers, such as L-methionine and gentisic acid, are disclosed, wherein the compounds are based on sarcophagine ligands coordinated to a radioisotope, such as 64-copper, and linked to a tetrazine group for reaction with tumour targeting antibodies having functional reactive groups such as trans-cyclooctene, processes of preparing said radioligand formulations, and uses thereof for radioimaging, diagnosing and treating cancer.